InterventionsHumans

Cardiovascular and Rhythm Benefits of GLP-1 Receptor Agonists in Obese Patients: A Real-World Multicenter Study

AHA Scientific Sessions 2025 Abstract

The paper

Yousafzai O, Annie F, Kanwal K et al.

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4368969

doi.org/10.1161/circ.152.suppl_3.4368969

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
Neurology Genetics · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026